Structure Therapeutics shares surged Monday after the biotech said its daily pill helped patients lose up to 39 pounds over a 44-week study.

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which regulators could approve within weeks.

Structure Therapeutics' oral obesity drug aleniglipron delivered up to 16.3% weight loss when ​compared with a placebo after ...